A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of ABBV-277 in Healthy Adult Participants
Completed · Phase 1 · NCT07136103
Conditions: Healthy Volunteers
At a glance
- Research payments reported, 2025
- $720
- U.S. investigators named
- 0
- Sites paid
- 0
- Planned or actual enrollment
- 32
About the trial
- Sponsor
- AbbVie
- Tested
- ABBV-277 (drug), Placebo (drug)
- Dates
- Started 2025-08-19; completion 2026-06-11
- Results posted
- Not yet
The objective of this study is to evaluate the safety, tolerability, immunogenicity and pharmacokinetics (PK ) properties following a single dose of ABBV-277 in healthy adult participants.
From ClinicalTrials.gov, last updated 2026-07-08. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $720 in research payments for this study in 2025 (3 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
- $720
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.